Avalo Therapeutics, Inc. (AVTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$16.79

From 52W high−27.55%

Volume3.18M

Market cap$888.65M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$16.79

From 52W high

−27.55%

Volume

3.18M

Market cap

$888.65M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.9x

P/E (TTM)

—

RSI (14)

37.1

MomentumView details →

1D Return

−0.72%

YTD Return

−8.98%

SummaryUpdated Jun 1, 2026

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a clinical-stage precision medicine company founded in 2011 and headquartered in Rockville, Maryland. Originally incorporated as Cerecor Inc., the company rebranded to Avalo Therapeutics in August 2021 to better reflect its focus on developing targeted therapeutics. The company went public in October 2015 and has since evolved into a biotechnology firm specializing in treatments for immunology, immuno-oncology, and rare genetic diseases where significant unmet medical needs exist.

Ask drillr about Avalo Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.9x

EV/Sales

8281.6x

P/S (TTM)

—

P/B (TTM)

2.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−22.36%

ROA (TTM)

−20.44%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−86.62%

EPS YoY

—

FCF YoY

−39.98%

Revenue CAGR 3Y

−85.16%

EPS CAGR 3Y

−35.19%

EBITDA YoY

−67.59%

MomentumView details →

1D Return

−0.72%

YTD Return

−8.98%

1Y Return

+39.73%

RSI (14)

37.1

vs 50D SMA

−11.89%

vs 200D SMA

−2.03%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

19.31x

Quick Ratio

19.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.83

EPS Surprise

−42.43%

Beats (12Q)

6/12

Next Q EPS Est

−$0.59

Avg Surprise (4Q)

1.10%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

59000.00

Net Income (TTM)

−100.33M

Op. CF (TTM)

−66.38M

Next earningsNov 5, 2026 →

Latest newsMore news →

Avalo Therapeutics announced its financial results for the second quarter of 2026.45d ago

Avalo Therapeutics announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, for development in hidradenitis suppurativa and other inflammatory disorders.96d ago

Similar companies

Faeth Therapeutics, Inc.FTH Inventiva S.A.IVA Theravance Biopharma, Inc.TBPH Immix Biopharma, Inc.IMMX Ardelyx, Inc.ARDX Cybin Inc. Common StockHELP Find similar companies →

Latest newsMore news →

Avalo Therapeutics announced its financial results for the second quarter of 2026.45d ago Avalo Therapeutics announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, for development in hidradenitis suppurativa and other inflammatory disorders.96d ago